Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial.

Cardiovasc Diabetol · 2021 · PMC8218391 · PMID 34158057

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In patients with type 2 diabetes, low HDL cholesterol, and recent ACS, the BETonMACE study showed a trend to decreased risk of MACE with apabetalone and fewer heart failure hospitalizations compared to placebo [ 7 , 20 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.